{"id":1077979,"date":"2026-07-09T07:48:17","date_gmt":"2026-07-09T07:48:17","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/1077979\/"},"modified":"2026-07-09T07:48:17","modified_gmt":"2026-07-09T07:48:17","slug":"astrazeneca-stock-dives-9-after-heart-drug-trial-misses-target","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/1077979\/","title":{"rendered":"AstraZeneca stock dives 9% after heart drug trial misses target"},"content":{"rendered":"<p>Shares of <a href=\"https:\/\/www.cnbc.com\/quotes\/AZN-GB\/\" rel=\"nofollow noopener\" target=\"_blank\">AstraZeneca<\/a> fell as much as 9% after a late stage clinical trial for an experimental heart disease failed to meet its target. <\/p>\n<p>The medicine, Wainua, did <a href=\"https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2026\/update-cardio-ttransform-phase-iii-trial.html\" target=\"_blank\" rel=\"nofollow noopener\">not reach its main goal<\/a> of reducing deaths and recurrent heart-related emergencies over 140 weeks compared to a placebo, the British drugmaker said in a press release early Thursday.<\/p>\n<p>The treatment is for a rare, life-threatening heart condition called transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).<\/p>\n<p>The stock was last seen down 8.9% in London, on track for its worst day since March 2020 at the start of the Covid-19 outbreak.<\/p>\n<p><strong>This is breaking news. Please refresh for updates.<\/strong><\/p>\n<p><a href=\"https:\/\/www.google.com\/preferences\/source?q=https:\/\/www.cnbc.com\/\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Shares of AstraZeneca fell as much as 9% after a late stage clinical trial for an experimental heart&hellip;\n","protected":false},"author":2,"featured_media":1077980,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[4316],"tags":[30888,5189,3085,31702,105,20944,4348,128389,5489,16,15],"class_list":["post-1077979","post","type-post","status-publish","format-standard","has-post-thumbnail","category-healthcare","tag-astrazeneca-plc","tag-breaking-news-europe","tag-business-news","tag-gilead-sciences-inc","tag-health","tag-health-care-industry","tag-healthcare","tag-ionis-pharmaceuticals-inc","tag-pharmaceuticals","tag-uk","tag-united-kingdom"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/116888922235738428","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/1077979","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=1077979"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/1077979\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/1077980"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=1077979"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=1077979"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=1077979"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}